EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional treatments by 38%, it failed to prove non-inferiority to the comparator drug aflibercept. In response, EyePoint is halting its wet AMD trials early, cutting its workforce by 53%, and shifting focus to DURAVYU's development for diabetic macular edema, with Phase 3 results expected in late 2027. Citigroup lowered its price target from $17 to $4 but maintained a Buy rating.
EyePoint's recent trial results provide context for health-sector market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 22:21 WIB: Among 150 priced health-sector US stocks, 73 rose and 70 fell today. Notable movers include MESO (Mesoblast Limited) at USD 12.00 with a -9.64% change and a typical hold time of 16 days, IBRX (ImmunityBio Inc. Common Stock) at USD 8.51 down 7.35% with a 3-day hold, and SMMT (Summit Therapeutics Inc) at USD 15.68 up 7.18% with a 17-day hold time.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
Marvell Technology executive Bharathi Sandeep sold 3,685 shares worth about $865,864 amid market pressure on AI chip stocks following warnings from Broadcom's CEO about AI funding. Despite strong AI-related results, Marvell's stock faces valuation co...
